Stereotaxis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 09:00 am EDT
Share
Stereotaxis, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 7.86 million compared to USD 6.15 million a year ago. Net loss was USD 4.96 million compared to USD 5.13 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.07 a year ago. Diluted loss per share from continuing operations was USD 0.07 compared to USD 0.07 a year ago.
For the six months, revenue was USD 14.41 million compared to USD 13.19 million a year ago. Net loss was USD 10.3 million compared to USD 9.22 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.13 a year ago. Diluted loss per share from continuing operations was USD 0.14 compared to USD 0.13 a year ago.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Companyâs primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.